AZD0780 [2455427-91-3]

TargetMol Chemicals

AZD0780 [2455427-91-3]

4

Chemical

Research Use Only

AZD0780

99.74%

C20H20F2N6O2

414.41

AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.

3 years

FC(F)Oc1cnc(N[C@H]2CC[C@@H](C2)Nc2ccc(cn2)-n2ccccc2=O)nc1

-20°C

12352200